Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.
Related Articles
Brexpiprazole with Sertraline Significantly Reduces PTSD Symptoms in 10 Days
A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February…
FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity
Tirzepatide’s approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.
FDA Issues CRL for Sotagliflozin in Type 1 Diabetes and CKD
The FDA’s decision not to approve sotagliflozin as an adjunct in T1D and CKD comes less than 2 months after a negative advisory committee meeting…
AI-Powered Prostate Cancer Grading Predicts Active Surveillance Outcomes – Cornelia Ding
Andrea Miyahira interviews Cornelia (Chien-Kuang) Ding about her study on predicting prostate cancer grade reclassification using a deep learning-based grading algorithm. Dr. Ding discusses their…
Harnessing Artifical Intelligence in Bladder Cancer: Digital Tools for Enhanced Diagnosis and Treatment – David McConkey
David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology. He outlines ongoing collaborations between cooperative groups and…
Advancing Female Bladder Cancer Care: Insights from AUA’s First Specialized Course – Armine Smith
Ashish Kamat introduces Armine Smith to discuss the intricacies of treating female bladder cancer, emphasizing organ and sexual function preservation during radical cystectomy. Highlighting a…
MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression – Neil Fleshner
Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance…
FDA Approves First Acellular Tissue Vessel Therapy for Extremity Vascular Trauma
The ATEV therapy, named Symvess, provides revascularization when autologous vein graft or implantation of a synthetic graft is not feasible.
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
